Endothelial progenitor cells (EPCs) have been isolated and shown to be effective in animal
models of ischemia, and many groups involved in clinical trials have demonstrated that EPC …

The age-adjusted prevalence of peripheral arterial disease in the US population was
estimated to approach 12% in 1985, and as the population ages, the overall population …

Potential applications of tissue engineering in regenerative medicine range from structural
tissues to organs with complex function. This review focuses on the engineering of heart …

Tissue engineering requires formation of a de novo stable vascular network. Because of
their ability to proliferate, differentiate into endothelial cells, and form new vessels, blood …

Historically, revascularization of ischemic tissue was believed to occur through the migration
and proliferation of endothelial cells in nearby tissues; however, evidence accumulated in …

Recruitment of human CD34+ progenitor cells toward vascular lesions and differentiation
into vascular cells has been regarded as a critical initial step in atherosclerosis. Previously …

Bone marrow-derived CD34+ cells are a well-characterized population of stem cells that
have traditionally been used clinically to reconstitute the hematopoietic system after …

CD34+ bone marrow–derived progenitor cells contribute to tissue repair by differentiating
into endothelial cells, vascular smooth muscle cells, hematopoietic cells, and possibly other …

The homing and differentiation mechanisms of endothelial progenitor cells (EPCs) at sites of
vascular lesions are unclear. To investigate whether platelets play a role in the recruitment …

Ischemic cardiovascular events are a major cause of death globally. Endothelial progenitor
cell (EPC)-based approaches can result in improvement of vascular perfusion and might …